An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

Yoshinobu Maeda; Hisakazu Nishimori; Yoshihiro Inamoto; Hirohisa Nakamae; Masashi Sawa; Yasuo Mori; Kazuteru Ohashi; Shin ichiro Fujiwara; Mitsune Tanimoto

An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

Yoshinobu Maeda, Hisakazu Nishimori, Yoshihiro Inamoto, Hirohisa Nakamae, Masashi Sawa, Yasuo Mori, Kazuteru Ohashi, Shin ichiro Fujiwara, Mitsune Tanimoto

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

Original language	English
Pages (from-to)	409-412
Number of pages	4
Journal	Acta Medica Okayama
Volume	70
Issue number	5
Publication status	Published - 2016
Externally published	Yes

All Science Journal Classification (ASJC) codes

General Biochemistry,Genetics and Molecular Biology

Cite this

@article{df54f11c1ab841f78202a392af85f8bd,

title = "An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease",

abstract = "Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.",

author = "Yoshinobu Maeda and Hisakazu Nishimori and Yoshihiro Inamoto and Hirohisa Nakamae and Masashi Sawa and Yasuo Mori and Kazuteru Ohashi and Fujiwara, {Shin ichiro} and Mitsune Tanimoto",

note = "Publisher Copyright: {\textcopyright} 2016 by Okayama University Medical School.",

year = "2016",

language = "English",

volume = "70",

pages = "409--412",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "5",

}

TY - JOUR

T1 - An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

AU - Maeda, Yoshinobu

AU - Nishimori, Hisakazu

AU - Inamoto, Yoshihiro

AU - Nakamae, Hirohisa

AU - Sawa, Masashi

AU - Mori, Yasuo

AU - Ohashi, Kazuteru

AU - Fujiwara, Shin ichiro

AU - Tanimoto, Mitsune

PY - 2016

Y1 - 2016

N2 - Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

AB - Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

UR - http://www.scopus.com/inward/record.url?scp=84997706142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997706142&partnerID=8YFLogxK

M3 - Article

C2 - 27777437

AN - SCOPUS:84997706142

SN - 0386-300X

VL - 70

SP - 409

EP - 412

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 5

ER -

An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this